NasdaqGS - Nasdaq Real Time Price USD
Day One Biopharmaceuticals, Inc. (DAWN)
As of 2:27 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 10 | 10 | 11 |
| Avg. Estimate | -0.41 | -0.63 | -1.76 | -1.86 |
| Low Estimate | -0.73 | -1.08 | -2.23 | -4.29 |
| High Estimate | 0.3 | -0.4 | -0.79 | -0.26 |
| Year Ago EPS | -0.54 | -0.64 | -2.37 | -1.76 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 9 | 9 | 10 |
| Avg. Estimate | 22.23M | 17.51M | 46.52M | 129.71M |
| Low Estimate | 9.75M | 11.46M | 29.4M | 63.49M |
| High Estimate | 83M | 23.7M | 107M | 176.3M |
| Year Ago Sales | -- | -- | -- | 46.52M |
| Sales Growth (year/est) | -- | -- | -- | 178.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.6 | -0.58 | -0.66 | -0.75 |
| EPS Actual | -0.54 | -0.64 | -0.72 | -0.05 |
| Difference | 0.06 | -0.06 | -0.06 | 0.7 |
| Surprise % | 10.00% | -10.30% | -9.10% | 93.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.41 | -0.63 | -1.76 | -1.86 |
| 7 Days Ago | -0.42 | -0.63 | -1.78 | -1.9 |
| 30 Days Ago | -0.42 | -0.64 | -1.78 | -1.81 |
| 60 Days Ago | -0.42 | -0.64 | -1.78 | -1.81 |
| 90 Days Ago | -0.76 | -0.63 | -2.7 | -2.17 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 2 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DAWN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 24.10% | -- | -- | 4.10% |
| Next Qtr. | 1.60% | -- | -- | 7.60% |
| Current Year | 25.70% | -- | -- | 2.50% |
| Next Year | -5.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Maintains | Needham: Buy to Buy | 10/9/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 8/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2024 |
| Upgrade | B of A Securities: Underperform to Buy | 8/1/2024 |
| Maintains | Needham: Buy to Buy | 7/31/2024 |
| Reiterates | Needham: Buy to Buy | 7/30/2024 |
Related Tickers
URGN UroGen Pharma Ltd.
12.71
+0.87%
PDSB PDS Biotechnology Corporation
3.0999
-2.22%
SWTX SpringWorks Therapeutics, Inc.
30.75
+2.09%
LRMR Larimar Therapeutics, Inc.
7.57
-1.82%
MREO Mereo BioPharma Group plc
4.6100
+2.22%
XFOR X4 Pharmaceuticals, Inc.
0.5130
-3.75%
CGEM Cullinan Therapeutics, Inc.
17.51
-0.57%
IMTX Immatics N.V.
9.46
+0.11%
CYTK Cytokinetics, Incorporated
54.52
-1.37%
BPMC Blueprint Medicines Corporation
86.72
-2.92%